RAHWAY, N.J., December 17, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial ...

RAHWAY, N.J., November 21, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

The drug is known chemically as pembrolizumab. "It's technically called a checkpoint inhibitor," Dr. Len Lichtenfeld, Chief Medical Officer of the American Cancer Society, said. "It's one of several ...

RAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced that the Phase ...

For Merck & Co., the oncology show has been all about Keytruda but also about Lynparza and Lenvima for the past few years. But the New Jersey pharma is hoping to soon have some supporting players to ...

Merck, known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-716 trial investigating KEYTRUDA, Merck’ s anti-PD-1 therapy, met its primary endpoint of ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...

KEYTRUDA is a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA blocks the interaction between PD-1 and its ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong. The ...

First and only systemic therapy to improve survival when used before and after surgery for patients with MIBC who are ineligible for cisplatin-based chemotherapy First ever positive Phase 3 study in ...